Heron Therapeutics

Heron Therapeutics develops medicines for people facing pain or nausea after surgery or cancer treatment. Its products help patients avoid discomfort during recovery or chemotherapy. The company’s solutions are used in hospitals and clinics across the United States.

Pain Relief, Nausea Control: Heron’s Main Offerings

Oncology Care (77% of Q3 2024 sales): CINVANTI and SUSTOL prevent nausea and vomiting from chemotherapy for cancer patients.

Acute Care (23% of Q3 2024 sales): ZYNRELEF and APONVIE manage pain and nausea after surgery for hospital patients.

Growth Spurts and Strategic Moves

Partnered with CrossLink Life Sciences in 2024 to expand ZYNRELEF’s orthopedic sales reach.

Launched APONVIE in March 2023, entering the post-surgery nausea market.

Secured expanded FDA approval for ZYNRELEF in January 2024 and new device approval in September 2024.

ZYNRELEF received CMS reimbursement status effective April 1, 2022, while APONVIE received it effective April 1, 2023.

Restructured operations in 2023, reducing costs and headcount to improve efficiency.

Why Heron Stands Out in the Crowd

Heron’s Biochronomer technology allows single-dose, extended-release medicines, reducing the need for repeat dosing. Manufacturing improvements have reduced costs in 2024.

Five Things You Need to Know

Net product sales in Q3 2024 were $32.8 million, up from $31.4 million in Q3 2023.

Oncology care products accounted for 77.5% of net product sales in Q3 2024.

Gross margin was approximately 71% in both Q3 and the first nine months of 2024, based on GAAP figures.

Net loss (GAAP) for Q3 2024 was $4.8 million, down from $25.0 million in Q3 2023.

Cash and short-term investments totaled $70.9 million as of September 30, 2024 (end of Q3 2024).

Bottom Line

Heron has shifted from research to commercial sales, focusing on pain and nausea solutions for hospitals and cancer clinics. The company continues to adapt through new partnerships, product launches, and cost controls.